Plain-English translation of NCT06971744 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether and mesylate, given together with an existing maintenance treatment called , can help prevent high-grade serous ovarian cancer from returning after chemotherapy. The study involves about 38 patients at a single medical center. Researchers want to see if this medication combination is both safe and effective at keeping the cancer in remission longer.
Ovarian cancer often comes back even after successful chemotherapy, and doctors need better ways to prevent this recurrence. This medication combination is based on early research suggesting it may help maintain remission, and this trial will determine whether it actually works for patients.
You likely qualify if…
You likely don't qualify if…
You would take two oral medications three times daily and receive intravenous infusions of every three weeks. The trial will carefully monitor your safety during the first three weeks, then continue treatment as long as the cancer stays controlled and side effects remain manageable. You will have regular blood tests and imaging scans to check how well the treatment is working and watch for any problems.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States